The sample copy of this report is available for access.
The North America Artificial Intelligence In Precision Medicine Market is expected to reach USD 11.7 billion by 2032, growing at a CAGR of 37.3% during (2026 - 2033).
The North America Artificial Intelligence In Precision Medicine Market evolved from early machine-learning applications in genomics and diagnostics into a broader ecosystem spanning predictive analytics, medical imaging, biomarker discovery, drug development, and clinical decision support. Advances in big-data infrastructure, electronic health records, molecular profiling, and real-world evidence enabled AI platforms to process increasingly complex clinical and biological datasets. Growing regulatory accommodation for AI-enabled medical technologies further encouraged commercialization. The market now reflects structured collaboration among technology companies, healthcare providers, research institutions, and pharmaceutical organizations deploying AI across personalized diagnostics and therapeutic workflows.
Multi-omics integration, explainable AI, predictive analytics, and decentralized precision care are shaping current market development. Providers increasingly combine genomics, proteomics, metabolomics, imaging, electronic health records, and real-world evidence to improve biomarker discovery, patient stratification, and individualized treatment selection. Greater emphasis on transparency and interpretability is strengthening clinician confidence and regulatory readiness, while AI-enabled telemedicine, wearable monitoring, and remote data collection extend precision medicine beyond traditional clinical environments. Investment in cloud computing, interoperability, cybersecurity, and advanced computational infrastructure is also supporting wider clinical and research adoption.
Based on Component, the market is segmented into Software, Services, and Hardware. The Software market dominated the North America Artificial Intelligence In Precision Medicine Market by Component in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 4.8 billion by 2032, growing at a CAGR of 36.7 % during the forecast period. The Services market is expected to witness a CAGR of 37.8% during (2026 - 2033). The Hardware market is expected to witness a CAGR of 37.7% during (2026 - 2033).
Software represents the core analytical layer, encompassing predictive analytics, genomic interpretation, clinical decision support, patient stratification, and AI-driven treatment planning supported by machine learning, deep learning, and natural language processing. Services include consulting, implementation, system integration, customized algorithm development, training, validation, maintenance, and workflow optimization required to operationalize AI across healthcare institutions and research environments. Hardware includes high-performance computing systems, GPUs, AI-optimized processors, edge infrastructure, medical imaging equipment, and other computational resources required to process large biomedical datasets and execute AI models efficiently.
Based on Technology, the market is segmented into Deep Learning, Natural Language Processing, Querying Method, and Context Aware Processing. The Deep Learning market dominated the North America Artificial Intelligence In Precision Medicine Market by Technology in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 3.7 billion by 2032, growing at a CAGR of 36.3 % during the forecast period. The Natural Language Processing market is expected to witness a CAGR of 37.5% during (2026 - 2033). Additionally, The Querying Method market is expected to witness highest CAGR of 38% during (2026 - 2033).
Deep Learning supports high-dimensional biomedical analysis across medical imaging, pathology, genomic sequencing, and multi-omics datasets, enabling automated feature extraction and predictive modeling. Natural Language Processing converts unstructured clinical notes, electronic health records, scientific literature, and other textual data into actionable insights for patient stratification and clinical decision support. Querying Method facilitates efficient access and analysis of large biomedical databases, genomic repositories, treatment records, and clinical-trial datasets. Context Aware Processing evaluates patient-specific clinical, physiological, historical, and environmental factors to generate more adaptive and clinically relevant precision-medicine recommendations.
Based on Therapeutic Application, the market is segmented into Oncology, Cardiology, Neurology, Respiratory, and Other Therapeutic Application. Oncology applies AI to genomic sequencing, tumor profiling, image interpretation, biomarker identification, therapy selection, resistance prediction, and clinical-trial matching, making it an advanced area of precision-medicine adoption. Cardiology uses AI for cardiovascular risk stratification, imaging analysis, arrhythmia detection, wearable-data interpretation, and personalized disease management.
Neurology incorporates AI into neuroimaging, biomarker discovery, disease-progression prediction, and treatment planning for conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and epilepsy. Respiratory applications include imaging interpretation, pulmonary-function analysis, exacerbation prediction, and remote monitoring, while Other Therapeutic Application covers autoimmune diseases, rare genetic disorders, infectious diseases, metabolic conditions, and additional emerging precision-medicine use cases.
Free Valuable Insights: The Global Artificial Intelligence In Precision Medicine Market will hit USD 31628.6 Million billion by 2033, at a CAGR of 37.8%
Based on Country, the market is segmented into US, Canada, Mexico, and Rest of North America. The US market dominated the North America Artificial Intelligence In Precision Medicine Market by Country in 2025, and would continue to be a dominant market till 2033; thereby, achieving a market value of USD 8.6 billion by 2032, growing at a CAGR of 36.4 % during the forecast period. The Canada market is expected to witness a CAGR of 39.5% during (2026 - 2033). Additionally, The Mexico market is expected to witness a CAGR of 40.3% during (2026 - 2033).
Across North America, AI-enabled precision medicine is being shaped by multi-omics analytics, predictive modeling, regulatory evolution, clinical validation, and healthcare-data integration. The US emphasizes AI-driven oncology, real-world evidence, genomic analytics, explainability, federated learning, and clinical workflow integration, while Canada focuses on drug repurposing, localized genomic models, explainable AI, regulatory alignment, and collaboration between technology firms and healthcare institutions. Mexico is advancing AI-enabled early detection, personalized treatment, localized clinical models, international partnerships, and cloud-supported deployment, whereas Rest of North America emphasizes biomarker discovery, interpretable AI, biomanufacturing, multimodal analytics, and scalable precision-medicine platforms adapted to regional healthcare requirements.
By Component
By Technology
By Therapeutic Application
By Country
Set to reach $11.7 Billion by 2032, growing at 37.3% CAGR during 2026-2033.
The US leads with $8.6 billion by 2032, growing at 36.4% CAGR during 2026-2033.
Software segment will reach $4.8 billion by 2032, growing at 36.7% CAGR during 2026-2033.
Software segment achieves $4.8 billion by 2032, growing at 36.7% CAGR during 2026-2033.
Canada market is expected to witness a CAGR of 39.5% during 2026-2033.
Mexico market is expected to witness a CAGR of 40.3% during 2026-2033.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 